Needham analyst Ryan MacDonald lowered the firm’s price target on DocGo to $7 from $10 and keeps a Buy rating on the shares. The analyst cites the company having materially lowered guidance for FY24 after an April announcement that they will provide accelerated transition assistance to a new provider of services for sites in NYC concurrent with the expiration of the original terms of its HPD contract in May. The $110M guide down was certainly disappointing, but it was somewhat expected by investors, and DocGo used the quarter as an opportunity to clear the deck, giving investors a fresh look at the fundamental profile of the core business, the firm added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DCGO:
- DocGo price target lowered to $6.50 from $8 at Stifel
- DocGo price target lowered to $9 from $10 at Canaccord
- DocGo signs extension, starts transition of asylum seeker contract with NYC HPD
- DocGo contract transition could remove overhang, says Canaccord
- DocGo’s Subsidiary Renews NYC Asylum Seeker Support Contract